Osisko Development Corp. — Capital/Financing Update 2026

Jan 28, 2026

{0}------------------------------------------------

March 2, 2021

VIA SEDAR

Ontario Securities Commission Alberta Securities Commission British Columbia Securities Commission The Manitoba Securities Commission Financial and Consumer Affairs Authority of Saskatchewan Office of the Superintendent of Securities, Newfoundland and Labrador New Brunswick Financial and Consumer Services Commission Nova Scotia Securities Commission Office of the Superintendent of Securities, Prince Edward Island

Dear Sirs/Mesdames:

Re: MediPharm Labs Corp. (the "Company") –

Prospectus Supplement dated March 2, 2021 to the Short Form Base Shelf Prospectus dated February 24, 2021 (the "Supplement")

We hereby consent to the reference to our firm name on the cover page of the Prospectus Supplement, and consent to the use of our firm name and the reference to our opinion under the headings "Eligibility for Investment" and "Certain Canadian Federal Income Tax Considerations".

We confirm that we have read the Prospectus Supplement and that we have no reason to believe that there are any misrepresentations in the information contained in the Prospectus Supplement that:

• (a) are derived from our opinions referred to above; or
• (b) are within our knowledge as a result of the services that we performed to render such opinions.

This letter is delivered to the addressees pursuant to the requirements of securities legislation.

Yours very truly,

(signed) "AIRD & BERLIS LLP"